The PwC Strategy& 2022 Global CDMO Study of Pharmaceutical Operations highlights the competitive advantage that pharmaceutical companies can gain by partnering with contract development and manufacturing organizations (CDMOs) in a rapidly changing supply ecosystem. The study notes that the global Covid-19 pandemic and geopolitical tensions have led to significant shifts in the pharmaceutical supply chain, with treatments increasingly being produced by highly capable CDMOs. The study also highlights the emergence of advanced therapies (ATx) that complement traditional treatments, and the role that CDMOs can play in supporting the development and production of these therapies. The study concludes that CDMOs can provide pharmaceutical companies with access to specialized capabilities, flexible capacity, and a global network, enabling them to accelerate product development, improve operational efficiency, and reduce risk.
